- Home
- LEU vs AUTL Comparison
LEU vs AUTL Comparison
Compare LEU & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEU | AUTL |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 433.8M |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LEU | AUTL |
|---|---|---|
| Price | $240.51 | $1.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $243.00 | $8.67 |
| AVG Volume (30 Days) | 871.8K | ★ 2.7M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 6.17 | N/A |
| Revenue | ★ $454,100,000.00 | $51,128,000.00 |
| Revenue This Year | $1.17 | $669.49 |
| Revenue Next Year | $8.96 | $91.53 |
| P/E Ratio | $39.35 | ★ N/A |
| Revenue Growth | 15.25 | ★ 406.67 |
| 52 Week Low | $49.40 | $1.11 |
| 52 Week High | $464.25 | $2.80 |
Technical Indicators
Market Signals| Indicator | LEU | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 70.58 |
| Support Level | $244.38 | $1.63 |
| Resistance Level | $263.73 | $1.79 |
| Average True Range (ATR) | 18.61 | 0.10 |
| MACD | 1.46 | 0.04 |
| Stochastic Oscillator | 35.08 | 81.37 |
Price Performance
Historical ComparisonAbout LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.